Document Detail


Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance.
MedLine Citation:
PMID:  19356003     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiovascular diseases are the most common cause of mortality and morbidity accounting for more than 40% of total mortality in Western countries, most of which is due to acute coronary syndromes (ACS), including ST and non-ST elevation myocardial infarction. An optimal pharmacological approach in these patients is of major importance with a particular emphasis on the antiplatelet regimen, which remains the cornerstone of the initial ACS treatment at hospital admission and during percutaneous coronary interventions (PCI). This review briefly discusses the pathogenesis of ACS, and updates the available pharmacological antithrombotic strategies with a particular focus on aspirin and clopidogrel resistance, which has caused major concern, especially in the modern era of interventional cardiology. Persistent platelet reactivity despite aspirin or clopidogrel intake is probably a risk factor for the recurrence of ischemic events. Despite a lack of uniformly accepted definitions of aspirin and clopidogrel resistance, we provide an objective description of what is already proved and what remains to be established. In clopidogrel poor-responders, preliminary data suggest that increasing the loading dose might be beneficial prior to PCI, while trials on the potential benefit of an increased maintenance dose after PCI are ongoing. Overall, data on the mechanisms and the management of platelet hyperactivity or antiplatelet drug biological resistance are still scarce and further studies are needed.
Authors:
Robert F Bonvini; Jean-Luc Reny; François Mach; Thomas Zeller; Pierre Fontana
Related Documents :
11577263 - Low molecular weight heparin therapy for percutaneous coronary intervention: a practice...
16162023 - Eptifibatide: a review of its use in patients with acute coronary syndromes and/or unde...
22679253 - Missed cardiac tamponade.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current vascular pharmacology     Volume:  7     ISSN:  1570-1611     ISO Abbreviation:  Curr Vasc Pharmacol     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-09     Completed Date:  2009-06-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101157208     Medline TA:  Curr Vasc Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  198-208     Citation Subset:  IM    
Affiliation:
Angiology Division, Heart Center, Bad Krozingen, Germany. Robert.Bonvini@hcuge.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy*,  physiopathology,  therapy
Angioplasty, Transluminal, Percutaneous Coronary / methods
Aspirin / pharmacology,  therapeutic use
Clinical Trials as Topic
Drug Resistance
Fibrinolytic Agents / pharmacology,  therapeutic use*
Humans
Platelet Aggregation Inhibitors / pharmacology,  therapeutic use*
Risk Factors
Ticlopidine / analogs & derivatives,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Involvement of leukotriene pathway in the pathogenesis of ischemia-reperfusion injury and septic and...
Next Document:  Lifestyle choices and endothelial function: risk and relevance.